New HIV prevention shot could protect drug users
NCT ID NCT07199335
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 38 times
Summary
This study is testing whether a long-acting injectable HIV prevention drug, cabotegravir, works well for people who inject drugs. One hundred adults who have injected non-prescription drugs in the past 6 months and are at risk for HIV through sex will receive the shot along with support services. Researchers will measure how many participants stick with the treatment after 7 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fenway Health
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabotegravir (injectable PrEP)
What this could lead to
If successful, this could provide a practical HIV prevention option for people who inject drugs, reducing new infections in this high-risk group.
What could go wrong
This is a small, early-phase feasibility study with only 100 participants, so results may not apply broadly. The drug is already approved for sexual HIV risk, but its effectiveness in this specific population is unproven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.